<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664716</url>
  </required_header>
  <id_info>
    <org_study_id>104RA202</org_study_id>
    <nct_id>NCT00664716</nct_id>
  </id_info>
  <brief_title>Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants</brief_title>
  <acronym>RESPOND</acronym>
  <official_title>Assessment Of Safety, Efficacy, PK&amp;PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and efficacy of BG9924 in RA participants that have had an inadequate response to
      disease-modifying anti-rheumatic drug (DMARD) therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate efficacy of BG9924 in combination with methotrexate (MTX) in RA participants who have had an inadequate response to DMARD therapy</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and tolerability of BG9924 in this participant population</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">391</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous administration of placebo given for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BG9924 - dosage level administered as per Biogen Idec protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BG9924 - dosage level administered as per Biogen Idec protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BG9924 - dosage level administered as per Biogen Idec protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fourth Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BG9924 - dosage level administered as per Biogen Idec protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fifth Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BG9924 - dosage level administered as per Biogen Idec protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Baminercept alfa 1</intervention_name>
    <description>experimental - one dose level</description>
    <arm_group_label>One Dose</arm_group_label>
    <other_name>BG9924</other_name>
    <other_name>LT beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>BG9924</other_name>
    <other_name>LT beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Baminercept alfa 2</intervention_name>
    <description>experimental - second dose level</description>
    <arm_group_label>Second Dose</arm_group_label>
    <other_name>LT beta</other_name>
    <other_name>BG9924</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Baminercept alfa 3</intervention_name>
    <description>experimental - third dose level</description>
    <arm_group_label>Third Dose</arm_group_label>
    <other_name>BG9924</other_name>
    <other_name>LT beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Baminercept alfa 4</intervention_name>
    <description>experimental - fourth dose level</description>
    <arm_group_label>Fourth Dose</arm_group_label>
    <other_name>BG9924</other_name>
    <other_name>LT beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Baminercept alfa 5</intervention_name>
    <description>experimental - fifth dose level</description>
    <arm_group_label>Fifth Dose</arm_group_label>
    <other_name>LT beta</other_name>
    <other_name>BG9924</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of RA (functional class I - III)

          -  Stable dose of MTX

          -  Inadequate response to at least one conventional DMARD therapy

        Key Exclusion Criteria:

          -  Serious local infection or systemic infection

          -  History (Hx) of recurrent infections requiring oral or parenteral anti-infective
             treatment

          -  Hx of tuberculosis (TB) or positive purified protein derivative (PPD) test during the
             screening period

          -  Clinical significant lab tests at screening

          -  Positive for Hep C or Hep B at screening

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Tucuman</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04027-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>H2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Cuernavaca</city>
        <zip>62270</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Torun</city>
        <zip>87100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Braila</city>
        <zip>810112</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <disposition_first_submitted>December 17, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 17, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 21, 2016</disposition_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>DMARD inadequate response</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

